← Leaderboards
Brad H Nelson
Benaroya Research Inst At Virginia Mason
$2,130,244
Attributed
$2,130,244
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,130,244 · 4
By mechanism
R01$1,752,244 · 2
R21$378,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Benaroya Research Inst At Virginia Mason
Same institution · by research overlap
- David J Rawlings$37,323,092
- Jane Hoyt Buckner$93,413,622
- Gerald T Nepom$318,570,989
- Hazel B Breitz$120,500
- Brad Stone$1,449,950
Others in their field
Top investigators on “Tumor Antigens”
- William R Green · Dartmouth College$32,738,211
- John H Sampson · Duke University$30,849,602
- Catherine Ju-Ying Wu · Broad Institute, Inc.$30,485,072
- Elizabeth Marion Jaffee · Johns Hopkins University$26,862,085
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$24,066,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Tumor AntigensHuman SubjectBreast NeoplasmsClinical ResearchBiological Signal TransductionCyclinsPhosphatidylinositol 3 KinaseProtooncogeneSite Directed MutagenesisTissue /Cell CultureT LymphocyteTranscription FactorCytokine ReceptorsInterleukin 2Gene MutationYeast Two Hybrid SystemLymphocyte ProliferationMitogen Activated Protein KinaseChimeric ProteinsNeoplasm /Cancer VaccineOncogenesVaccine DevelopmentWomen'S HealthNeoplasm /Cancer Classification /Staging
Grant awards (9)
IL2 RECEPTOR SIGNALING IN T LYMPHOCYTES$384,630
R01 · FY2002 · GM
NOVEL VACCINE TARGETS FOR EARLY STAGE BREAST CANCER$411,632
R01 · FY2001 · CA
IL2 RECEPTOR SIGNALING IN T LYMPHOCYTES$373,426
R01 · FY2001 · GM
IMMUNOLOGIC SCREENING FOR EARLY STAGE COLORECTAL CANCER$141,750
R21 · FY2001 · CA
MOUSE MODEL TO STUDY IMMUNE EVASION BY MAMMARY TUMORS$47,250
R21 · FY2001 · CA
IL2 RECEPTOR SIGNALING IN T LYMPHOCYTES$362,551
R01 · FY2000 · GM
NOVEL VACCINE TARGETS FOR EARLY STAGE BREAST CANCER$220,005
R01 · FY2000 · CA
IMMUNOLOGIC SCREENING FOR EARLY STAGE COLORECTAL CANCER$141,750
R21 · FY2000 · CA
MOUSE MODEL TO STUDY IMMUNE EVASION BY MAMMARY TUMORS$47,250
R21 · FY2000 · CA